We produce over 50 drugs in almost 120 different dosage forms and strength. We are producing Active Pharmaceutical Ingredients (API), that have been used further to produce solid dosage forms of drugs. We are lunching second stage of investment in the modern oncological and immunosuppressive pharmaceuticals plant. We are proud especially because the congress, which took place between the 11th and 13th of December, was the most important academic and training event in Polish psychiatry in the last year. Our production capacity is 65 million of pack per year (tablets and capsules). Our product have broad usage in the public healthcare system. Our product have been used by the doctors to heal patients during the different parts of the therapy. The building will include a laboratory area for quality control, dedicated to product testing and a laboratory area for the R&D department.
Warsaw, Poland
Founded in 1823
1001-5000 Employees
Working industry
Pharmaceuticals
Type of company
Manufacturer
Ownership structure
Public Company
Locations
1 Headquarter
Number of products
10 Products
Specialised areas
Antibiotics, insulin, Medicine, CNS, Pharmaceuticals
Polfa Tarchomin S.A. offers a wide range of products and services
Product
The New Production Department of Sterile Forms “Ampoule Facility” - Polfa Tarchomin
Go to product >
Product
Tonasen – a new product in our offer, 26.09.2013 - Polfa Tarchomin
Go to product >
Product
OSŁONIK MAX Junior - Polfa Tarchomin
Go to product >
Product
ZINADERMIN - Polfa Tarchomin
Go to product >
Product
GOLDisept - Polfa Tarchomin
Go to product >
Product
MICONAL - Polfa Tarchomin
Go to product >
Product
OSŁONIK MAX EXTRA - Polfa Tarchomin
Go to product >
Product
POLDERMIN HYDRO - Polfa Tarchomin
Go to product >
An estimation about the ESG values based on digital data and signals. Important: The ESG scores are only based on information about the country, not the actual company itself
Country:
Poland
Overall risk estimation:
Low
The ESG Data of countries are based on public sources
Environment
B
Grade (A-E)
View details
Social
B
Grade (A-E)
View details
Governance
B
Grade (A-E)
View details
Get insights into the use cases of Polfa Tarchomin S.A.
Use case
Projekt dofinansowany ze środków budżetu państwa lub państwowych funduszy celowych - Polfa Tarchomin
Informacja o dofinansowaniu udzielonym przez Agencję Badań Medycznych stanowiącym pomocą publiczną, udzieloną na podstawie Rozdziału 2 Rozporządzenia Ministra Zdrowia z dnia 5 września 2019 r. w sprawie warunków i trybu udzielania pomocy publicznej i pomocy de minimis za pośrednictwem Agencji Badań Medycznych Rodzaj dotacji budżetowej lub nazwa programu lub funduszu: KONKURS ABM/2022/4 NA OPRACOWANIE I ROZWÓJ
Use case
Projekty dofinansowane z Funduszy Europejskich - Polfa Tarchomin
Rozbudowa infrastruktury badawczo – rozwojowej laboratorium przeznaczonego do celu kontroli i certyfikacji wyrobów medycznych: środków ochrony indywidualnej oraz masek medycznych” Projekt p.n. „Rozbudowa infrastruktury badawczo – rozwojowej laboratorium przeznaczonego do celu kontroli i certyfikacji wyrobów medycznych: środków ochrony indywidualnej oraz masek medycznych” jest współfinansowany przez Unię Europejską ze środków Europejskiego Funduszu Rozwoju Regionalnego w ramach
Polfa Tarchomin S.A. operates in 1 country around the world
Get an overview of the locations of Polfa Tarchomin S.A.
Location
Country
State
City
Headquarter
Poland
Masovian Voivodeship
Warsaw
Some frequent questions that have been asked about Polfa Tarchomin S.A.
Where is Polfa Tarchomin S.A. located?
The company headquarter of Polfa Tarchomin S.A. is located in Warsaw, Masovian Voivodeship, Poland. It's worth noting, that the company may have more locations
How many employees does Polfa Tarchomin S.A. approximately have?
As of the latest available information Polfa Tarchomin S.A. has around 1001-5000 employees worldwide.
When was Polfa Tarchomin S.A. founded?
Polfa Tarchomin S.A. was founded in 1823
In which industries does Polfa Tarchomin S.A. mainly work?
The company Polfa Tarchomin S.A. has it's main focus in the industries of Pharmaceuticals
Check out some interesting alternative companies to Polfa Tarchomin S.A.
Polpharma API
Starogard Gdański, Poland
1001-5000 Employees
-
We are proud of our 70 years of experience in supporting patients’ health with high quality APIs and becoming a leading European CDMO partner. API manufacturing is carried out in cGMP-compliant and FDA-approved multipurpose plant. Area dedicated to: POLPHARMA API PRODUCTION: 6,2 ha. Buildings dedicated to: Polpharma API production: 19.246 m2. API manufacturing is carried out in a cGMP-compliant and FDA-approved multipurpose plant. For over 80 years, trusted by patients, healthcare professionals, and business partners alike. A leading regional (CEE and CIS) manufacturer of pharmaceuticals and a leader in the Polish & Kazakhstan pharmaceutical market. Thanks to best-in-class industry talents and state-of-the-art technologies, we are able to design and deliver crucial products and solutions to address the biggest health challenges (an aging population, chronic diseases) and healthcare system problems (increasing healthcare costs, resource shortages).
Phytopharm Klęka S.A.
Nowe Miasto nad Wartą, Poland
251-500 Employees
1949
As we are constantly thinking about the future, we care for the environment by optimising energy consumption, segregating waste and starting pro-environmental projects. PHYTOPHARMAKON 2000 International Scientific Symposium is organised in Poznań to celebrate the 50th anniversary of the company. Our products are manufactured using the highest quality active ingredients with proven effectiveness and confirmed safety of use. We provide our customers with plant products intended for prevention and treatment. Consumers and pharmacists have trusted our products for many years. Many of the products rank top in their therapeutic categories. Therefore, we can safely say that it is one of the most advanced production facilities in the country. Pharmaceutical production starts — “Wytwórnia nr 11” (Factory No.
Medis Pharma B.V.
Haarlem, Netherlands
- Employees
2001
Our comprehensive portfolio currently includes about 185 pharmaceutical products covering a broad range of therapeutic areas. We offer a wide range of dosage forms including immediate and modified release tablets and capsules, soluble and oro-dispersible tablets, soft gel capsules, nasal suspensions, ointments, gels, oral liquids and injectables. Our vast experience in launching new products together with our proven regulatory skills, enable us to achieve fast and successful results. We offer range of specialist oncology products and product formulations, mainly in the form of tablets, capsules and injections.
3d Pharmaceuticals
Viluppuram, India
- Employees
-
The company has set up modern manufacturing facilities conforming to international standards. This will provide exclusive production facilities and increased capacity to manufacture oral liquids, oral solids and Nutraceutical products, apart from giving us the additional capacity to undertake contract manufacturing. These units are built to regulatory specifications and will be able to produce and supply products to the global market. Having a strong quality conscious associate WHO-GMP & GMP manufacturing facilities for bulk and finished products spread across India, we are efficiently backed up by an a team of excellent technocrats & professionals. Continuously offering unique products and services that would give customers utmost satisfaction and constantly working on smart marketing to maintain the clarity of product positioning Our core strength has been in creating, maintaining and sustaining mutually beneficial business relations with the Top Indian Players including national as well as Multinational Organizations in India. To become an International corporation in the field of Pharmaceutical healthcare industry by offering innovative quality products at affordable cost to the mankind. We operate with effective governance; maintain reputation of transparency, openness, fairness, and high standards of ethical behavior. Our company has always concentrated on developing manufacturing infrastructure needed to efficiently produce the basket of products we are traditionally well placed in - and have continually put in effort & resources to develop our site in Pondicherry into a world class manufacturing complex.
Huayi Pharmaceuticals
Hefei, China
251-500 Employees
2006
We provide security and fulfillment to our employees and strive for excellence in all that we do. We are accountable to our shareholders and make a profit for them over the long term by innovating and investing. We are experienced in technology transfers and scale-up process for commercial production. We manufacture quality generic medicines on a contractual basis for EU and Chinese customers with competitive pricing. We are confident in our ability to work with customers from all countries from our facilities in China. We manufacture solid oral dosage forms for customers in Europe and are adding liquid forms in 2020. We were granted our EU Good Manufacturing Practice (GMP) Certificate in 2010 following inspection by the UK Medicines and Healthcare Products Regulatory Agency (MHRA). Our dedication to manufacturing products of the highest quality can also be demonstrated by our facilities passing quality inspections by many customers including Novartis, Teva, Wockhardt, Genesis and Krka.
Chr. Olesen Synthesis A/S
Glostrup Municipality, Denmark
11-50 Employees
2011
Within amphetamines we are the only company to have a CEP for dexamphetamine sulphate and are also expanding into other amphetamines. We are also offering contract development and production services for new APIs and intermediates. Our primary product group within opioids is buprenorphine (APIs and intermediates), but we also have products like eg hydromorphone hcl. In addition we can offer a selection of non contolled APIs and advanced intermediates. Manufacturing is taking place in a well-equipped, up-to-date and efficient production facility comprising more than 8,000 m2 and including:. The selected product focus of COS is complementing its production setup, which is characterised by high flexibility and focus on small and medium-sized batches. Initial production of 4 APIs & 2 intermediates. Novartis acquired Hexal and merged it with Sandoz to create a leading generics player.